Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Publication Digest: Living Health Technology Assessment: Issues, Challenges and Opportunities

24 May 2023

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Thokala et al. introduced the concept of “Living Health Technology Assessment (HTA)”, which is considered to be an approach to address the issue of outdated reports by establishing a process for regular updates. The authors described the practical implementation of the “living HTA” approach including the challenges and considerations involved and highlighted scenarios where “living HTA” could be especially advantageous.

Access the full-text article here.